Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3930685 | 0.88 | PKM (0.58) | SMN1; SMN2PKMKDM4EALDH1A1GAA | |
| SCHEMBL4938503 | 0.87 | PKM (0.60) | SMN1; SMN2PKMKDM4EALDH1A1GAA | |
| SCHEMBL1811174 | 0.85 | SMN1; SMN2 (0.74) | SMN1; SMN2PKMKDM4EMAPTALDH1A1 | |
| SCHEMBL3929434 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2PKMKDM4EMAPTALDH1A1 | |
| SCHEMBL3923407 | 0.83 | SMN1; SMN2 (0.70) | SMN1; SMN2PKMKDM4EALDH1A1GAA | |
| SCHEMBL3930733 | 0.83 | SMN1; SMN2 (0.74) | SMN1; SMN2PKMKDM4EALDH1A1GAA | |
| SCHEMBL3918035 | 0.82 | SMN1; SMN2 (0.69) | SMN1; SMN2PKMKDM4EMAPTALDH1A1 | |
| SCHEMBL17478640 | 0.82 | SMN1; SMN2 (0.69) | SMN1; SMN2PKMKDM4EMAPTALDH1A1 | |
| SCHEMBL3920036 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2PKMKDM4EALDH1A1GAA | |
| SCHEMBL3919229 | 0.80 | SMN1; SMN2 (0.66) | SMN1; SMN2PKMKDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595314-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595314-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595314-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | ALBERATI-GIANI DANIELA | 2009-07-30 | — | — | US | disclosed |
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | ALBERATI-GIANI DANIELA | 2009-07-30 | — | — | US | disclosed |
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | ALBERATI-GIANI DANIELA | 2009-07-30 | — | — | US | disclosed |
| US-7427612-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427612-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427612-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1663232-B1 | 1-(2-AMINO-BENZOYL)-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | HOFFMANN LA ROCHE (CH) | 2007-10-03 | — | — | EP | disclosed |
| EP-1663232-B1 | 1-(2-AMINO-BENZOYL)-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | HOFFMANN LA ROCHE (CH) | 2007-10-03 | — | — | EP | disclosed |
| EP-1663232-A1 | 1-(2-AMINO-BENZOYL)-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| US-20050070539-A1 | Benzoyl-piperazine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2005-03-31 | — | — | US | disclosed |
| WO-2005023260-A1 | 1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070539-A1 | Benzoyl-piperazine derivatives | OPRL1, ACHE, PNMT | SMN1; SMN2 227/4885PKM 1456/4885KDM4E 1532/4885 |
| US-20090192136-A1 | BENZOYL-PIPERAZINE DERIVATIVES | OPRL1, ACHE, PNMT | SMN1; SMN2 227/4885PKM 1456/4885KDM4E 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.